线粒体自噬在骨肉瘤发展和治疗中的研究进展

doi:10.16352/j.issn.1001-6325.2025.10.1377

基础医学与临床 ›› 2025, Vol. 45 ›› Issue (10): 1377-1381.doi: 10.16352/j.issn.1001-6325.2025.10.1377

线粒体自噬在骨肉瘤发展和治疗中的研究进展

宁康盛, 云超, 李熠, 莫日格乐^*

内蒙古医科大学附属医院骨科,内蒙古呼和浩特 010010

收稿日期:2024-11-18 修回日期:2025-02-26 出版日期:2025-10-05 发布日期:2025-09-22
通讯作者: ^*morigele1979@163.com
基金资助:
内蒙古自治区第十二批草原英才创新人才团队;内蒙古医科大学致远人才计划善学类(ZY20242130)

Research progress on mitophagy in the development and treatment of osteosarcoma

NING Kangsheng, YUN Chao, LI Yi, Morigele^*

Department of Orthopedics, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010010, China

Received:2024-11-18 Revised:2025-02-26 Online:2025-10-05 Published:2025-09-22
Contact: ^*morigele1979@163.com

摘要/Abstract

摘要： 线粒体自噬作为一种高度保守的细胞防御机制,能精确识别并清除功能受损或过量的线粒体,从而维持线粒体网络的稳态,为细胞提供稳定的能量供应和生物合成所需原料。线粒体自噬通过多种分子机制对骨肉瘤的发展产生调控效应,针对这一机制作为治疗干预的新策略,为探索新型靶向疗法提供了坚实的理论基础与实践路径,从而推动骨肉瘤治疗领域向更加精确、高效的方向前进。

关键词: 骨肉瘤, 线粒体自噬, 细胞自噬, 代谢重编程, 信号通路

Abstract: Mitophagy, as a highly conserved cellular defense mechanism, precisely recognizes and eliminates dysfunctional or excessive mitochondria, thereby maintaining homeostasis of the mitochondrial network and providing a stable energy supply and raw materials for biosynthesis in cells. Mitophagy exerts regulatory effects on the development of osteosarcoma through multiple molecular mechanisms. Targeting this mechanism as a new strategy for therapeutic intervention provides a solid theoretical foundation and set stage for exploring novel targeted therapies, thereby driving the field of osteosarcoma treatment towards more precise and efficient directions.

Key words: osteosarcoma, mitophagy, cellular autophagy, metabolic reprogramming, signaling pathway

中图分类号:

R738.1

宁康盛, 云超, 李熠, 莫日格乐. 线粒体自噬在骨肉瘤发展和治疗中的研究进展[J]. 基础医学与临床, 2025, 45(10): 1377-1381.

NING Kangsheng, YUN Chao, LI Yi, Morigele. Research progress on mitophagy in the development and treatment of osteosarcoma[J]. Basic & Clinical Medicine, 2025, 45(10): 1377-1381.

参考文献

[1] Xu Y, Shi F, Zhang Y, et al. Twenty-year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors[J]. Int J Cancer,2024,154:226-240.
[2] 王磊,邱明宪,张慧荣,等.miR-499通过靶向TGF-α抑制人骨肉瘤细胞系Saos2迁移和促凋亡[J].基础医学与临床,2022,42:1230-1236.
[3] He G, Nie JJ, Liu X, et al. Zinc oxide nanoparticles inhibit osteosarcoma metastasis by downregulating β-catenin via HIF-1α/BNIP3/LC3B-mediated mitophagy pathway[J]. Bioact Mater,2022,19:690-702.
[4] Zheng Z, Zhao X, Yuan B, et al. Soy isoflavones induces mitophagy to inhibit the progression of osteosarcoma by blocking the AKT/mTOR signaling pathway[J]. Mol Med,2024, 30:5.doi: 10.1186/s10020-024-00778-y.
[5] Huang CF, Hsieh YH, Yang SF, et al. Mitophagy effects of protodioscin on human osteosarcoma cells by inhibition of p38MAPK targeting NIX/LC3 axis[J]. Cells,2023,12:395.doi: 10.3390/cells12030395.
[6] Zheng S, Luo M, Huang H, et al. New insights into the role of mitophagy related gene affecting the metastasis of osteosarcoma through scRNA-seq and CRISPR-Cas9 genome editing[J]. Cell Commun Signal,2024,22:592.doi: 10.1186/s12964-024-01989-w.
[7] Song C, Pan S, Zhang J, et al. Mitophagy: A novel perspective for insighting into cancer and cancer treatment[J]. Cell Prolif,2022,55:e13327.doi: 10.1111/cpr.13327.
[8] Righetti, Grillini, Del Dotto,et al.The pro-oncogenic protein IF1 promotes proliferation of anoxic cancer cells during re-oxygenation[J]. Int J Mol Sci,2023, 24, 14624.doi: 10.3390/ijms241914624.
[9] Lai HT, Naumova N, Marchais A, et al. Insight into the interplay between mitochondria-regulated cell death and energetic metabolism in osteosarcoma[J]. Front Cell Dev Biol,2022, 10:948097. doi: 10.3389/fcell.2022.948097。
[10] Giang AH, Raymond T, Brookes P, et al. Mitochondrial dysfunction and permeability transition in osteosarcoma cells showing the Warburg effect[J]. J Biol Chem,2013,288:33303-33311.
[11] Shen S, Xu Y, Gong Z, et al.Positive feedback regulation of circular RNA Hsa_circ_0000566 and HIF-1α promotes osteosarcoma progression and glycolysis metabolism[J]. Aging Dis,2023,14:529-547.
[12] Li T, Mao C, Wang X, et al.Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation[J]. J Exp Clin Cancer Res,2020,39:224.doi: 10.1186/s13046-020-01733-5.
[13] Sun W, Wang B, Qu XL, et al. Metabolism of reactive oxygen species in osteosarcoma and potential treatment applications[J]. Cells,2019,9:87.doi: 10.3390/cells9010087.
[14] Niemi NM, Friedman JR. Coordinating BNIP3/NIX-mediated mitophagy in space and time[J]. Biochem Soc Trans,2024,52:1969-1979.
[15] He G, Pan X, Liu X, et al.HIF-1α-mediated mitophagy determines ZnO nanoparticle-induced human osteosarcoma cell death both in vitro and in vivo[J].ACS Appl Mater Interfaces,2020,12:48296-48309.
[16] Shen W, Zeng X, Zeng X, et al.Trifluoperazine activates AMPK/mTOR/ULK1 signaling pathway to induce mitophagy in osteosarcoma cells[J].Chem Biol Interact, 2024,392:110904. doi: 10.1016/j.cbi.2024.110904.
[17] Chen L, Chen D, Pan Y, et al. Inhibition of mitochon-drial OMA1 ameliorates osteosarcoma tumorigenesis[J]. Cell Death Dis,2024, 15:786.doi: 10.1038/s41419-024-07127-1.
[18] Wu A, Yang ZK, Kong P, et al. Exploring osteosarcoma based on the tumor microenvironment[J]. Front Immunol,2024,15:1423194.doi: 10.3389/fimmu.2024.1423194.
[19] Wang Z, Wang Q, Cao H, et al. Mitochondrial localized in situ self-assembly reprogramming tumor immune and metabolic microenvironment for enhanced cancer therapy[J]. Adv Mater,2024,36:e2311043.doi: 10.1002/adma.202311043.
[20] Song Y, Zhou Y, Zhou X. The role of mitophagy in innate immune responses triggered by mitochondrial stress[J]. Cell Commun Signal, 2020,18:186. doi: 10.1186/s12964-020-00659-x.
[21] Gupta SS, Sharp R, Hofferek C,et al. NIX-mediated mitophagy promotes effector memory formation in antigen-specific CD8(+) T cells[J]. Cell Rep,2019,29:1862-1877.
[22] Xie W, Ma F, Dou L, et al. Allicin affects immunoreactivity of osteosarcoma cells through lncRNA CBR3-AS1[J]. Heliyon, 2024,10:e31971.doi: 10.1016/j.heliyon.2024.e31971.
[23] 姬健钧, 邱文奎. 氧化苦参碱通过COX-2/PINK1/Parkin信号通路介导的线粒体自噬对MG63骨肉瘤细胞的促凋亡机制[J]. 中国药房, 2024, 35: 44-50.
[24] Vianello, Cocetta, Catanzaro, et al. Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy[J]. Cell Death Dis, 2022,13:398. doi: 10.1038/s41419-022-04741-9.
[25] Zhan H, Xiao J, Wang P, et al. Exosomal CTCF confers cisplatin resistance in osteosarcoma by promoting autophagy via the IGF2-AS/miR-579-3p/MSH6 axis[J]. J Oncol,2022, 31:9390611. doi: 10.1155/2022/9390611.

线粒体自噬在骨肉瘤发展和治疗中的研究进展

Research progress on mitophagy in the development and treatment of osteosarcoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	高彦东, 边步荣, 王波. 异丙酚减轻结扎脊神经诱导的大鼠神经病理性疼痛[J]. 基础医学与临床, 2025, 45(8): 1028-1033.
[2]	贾纯亮, 梁磊, 李翰嵩, 王剑, 张磊, 李青科, 姚远. 灯盏花乙素抑制人胃癌细胞系MGC803增殖和迁移[J]. 基础医学与临床, 2025, 45(8): 1048-1053.
[3]	秦怡, 王晓燕. 蛋白酪氨酸激酶-2在妇科肿瘤中的作用[J]. 基础医学与临床, 2025, 45(8): 1098-1102.
[4]	于华惠, 杜智勇, 焦晓璐, 吕倩雯, 杨云云, 韩丽杰, 秦彦文. 血管生成素样蛋白8通过激活p53信号通路促进平滑肌细胞凋亡[J]. 基础医学与临床, 2025, 45(7): 882-888.
[5]	吴雪丽, 杨玉容, 保永莉, 吴汝成, 王莉莎, 陈阳. HAP1细胞有丝分裂过程中的动态转录物组研究[J]. 基础医学与临床, 2025, 45(6): 786-792.
[6]	秋昱翀, 杜文静. 苹果酸酶2通过调控SHCBP1促进肝癌的发生发展[J]. 基础医学与临床, 2025, 45(6): 741-747.
[7]	武波, 郭昊, 钟曌, 刘军芳, 王琦, 郭继勃. 过表达miR-101抑制JAK2/STAT3信号通路减缓急性心肌梗死模型大鼠心室重构[J]. 基础医学与临床, 2025, 45(3): 281-289.
[8]	邢雨润, 陈苏颖, 屠金恒, 何伯圣. 肠缺血/再灌注损伤对远端器官功能的影响[J]. 基础医学与临床, 2025, 45(3): 395-398.
[9]	靳高超, 邢盼盼, 王玉, 刘波. 乌司他丁联合生长抑素减轻急性胰腺炎大鼠肠道损伤[J]. 基础医学与临床, 2025, 45(2): 203-209.
[10]	庞昀婷, 任晓爽, 包涵, 孟凡青, 石枫. 左西孟旦减轻模型大鼠离体心脏停灌/再灌注损伤[J]. 基础医学与临床, 2025, 45(1): 65-69.
[11]	肖艳红, 姜明东, 林叶远, 冉灿, 梁博. 灯盏花乙素抑制人前列腺癌细胞系PC-3的增殖和迁移[J]. 基础医学与临床, 2024, 44(9): 1229-1235.
[12]	蒋苏, 吕新翔, 崔艳红, 吕李婷, 李东霞. 吴茱萸碱对特应性皮炎模型大鼠的治疗作用[J]. 基础医学与临床, 2024, 44(9): 1256-1262.
[13]	金庆, 丁佑铭. FOXC1在消化系统癌发生发展中作用的研究进展[J]. 基础医学与临床, 2024, 44(7): 1049-1053.
[14]	高寅洁, 童安莉. 醛固酮产生腺瘤中细胞死亡和增殖机制[J]. 基础医学与临床, 2024, 44(6): 758-762.
[15]	段然, 李青原, 冯同. 代谢重编程在特发性肺纤维化发病中的作用[J]. 基础医学与临床, 2024, 44(6): 882-886.